Citius Pharmaceuticals, Inc.
CTXRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCitius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. With a market capitalization of $15.0M, it sits in micro-cap territory. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Market Cap
$15.0M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-0.67
EPS (TTM)
$-2.47
EPS (Fwd)
$-0.81
ROE
-83.6%
ROA
-27.6%
Cash
$4.6M
Total Debt
$808,162
Free CF
-$33.5M
52W Change
-62.6%
Annual Financials
Cash vs Debt
Where CTXR stands vs its 150-day and 200-day moving averages
As of the June 25, 2026 close, CTXR finished 30.49% below its 150-day moving average ($0.82) and 40.00% below its 200-day moving average ($0.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTXR overbought or oversold?
At the June 25, 2026 close, CTXR's RSI(14) was 47.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Citius Pharmaceuticals, Inc. holds $4.6M in cash against $808K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$33.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -83.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Citius Pharmaceuticals, Inc.'s trajectory.